Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: Outcome after chemotherapy in 33 patients and review of the literature

Patricia Pautier, Alain Devidas, Alain Delmer, Herve Dombret, Laurent Sutton, Jean Marc Zini, Gerard Nedelec, Thierry Molina, Jean Pierre Marolleau, Pauline Brice

Research output: Contribution to journalArticlepeer-review

116 Citations (Scopus)

Abstract

We analyzed 33 patients with AILD T-NHL in a retrospective multicentric study. The median age was 62 yr (35-84 yr) (19 patients over 60 yr). Advanced disease (n = 31) and B-symptoms were consistently found (n = 29) and 20 patients had bone marrow involvement. The main laboratory abnormalities were: anemia (n = 13), hypereosinophilia (n = 13), lymphopenia (n = 14), hypergammaglobulinemia (n = 17), elevated lactate dehydrogenase (LDH) level (n = 24). First-line therapy was chemotherapy (ChT) alone (n = 25) or ChT after steroids (n = 8). Most patients received a CHOP-like regimen for a median number of 6 cycles and 3 patients received interferon α (IFNα) as consolidation after chemotherapy. With a median follow-up of 46 mo, 60% achieved a complete response but the outcome was poor with a relapse rate at 56%, a median survival referring to the total population was of 36 mo (2-108+ mo) and an overall survival at 5 yr of 36%. Two patients received high-dose chemotherapy (with total body irradiation) and autologous progenitor-cell transplantation for chemosensitive relapse and were free of disease at, respectively, 76 and 24 mo+. In conclusion AILD T-NHL still has a poor prognosis compared to other NHL. The role of intensive therapy and IFNα still remains to be evaluated.

Original languageEnglish
Pages (from-to)545-552
Number of pages8
JournalLeukemia and Lymphoma
Volume32
Issue number5-6
DOIs
Publication statusPublished - 1 Jan 1999
Externally publishedYes

Keywords

  • Angioimmunoblastic T-cell lymphomal
  • Chemotherapy
  • High-dose chemotherapy
  • Interferon α

Cite this